

Express Mail Label No.: EV392163147US  
Date of Deposit: July 13, 2004

Attorney Docket No.: 22058-521(GI5345)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith et al.

SERIAL NUMBER: 09/521,696

EXAMINER: J. Seharaseyon

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Supplemental Information Disclosure Statement is being filed after the mailing of an Office Action on the merits. The requisite fee under 37 C.F.R. § 1.17(p) is included. A copy of each of the references is enclosed. Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 22058-521.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

David E. Johnson, Reg. No. 41,874

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY AND POPEO, P.C.

Tel: (617) 542-6000

Fax: (617) 542-2241

Customer No. 30623

07/15/2004 YPOLITE1 00000041 09521696

02 FC:1806

180.00 0P

Express Mail No.: EV392163147US  
Date of Deposit: July 13, 2004

Page 1 of 1

Please type a plus sign (+) in this box

+



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/521,696
	<b>Filing Date</b>	March 9, 2000
	<b>First Named Inventor</b>	Keith
	<b>Group Art Unit</b>	1647
	<b>Examiner Name</b>	J. Seharaseyon
	<b>Attorney Docket Number</b>	22058-521

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	AL	Dorner et al., Interleukin-11, Biological Activity and Clinical Studies. BioDrugs, 8(6):418-29. (Dec. 1997)

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.